142 related articles for article (PubMed ID: 37777018)
1. Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo.
Guttman-Yassky E; Del Duca E; Da Rosa JC; Bar J; Ezzedine K; Ye Z; He W; Hyde C; Hassan-Zahraee M; Yamaguchi Y; Peeva E
J Allergy Clin Immunol; 2024 Jan; 153(1):161-172.e8. PubMed ID: 37777018
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K; Peeva E; Yamaguchi Y; Cox LA; Banerjee A; Han G; Hamzavi I; Ganesan AK; Picardo M; Thaçi D; Harris JE; Bae JM; Tsukamoto K; Sinclair R; Pandya AG; Sloan A; Yu D; Gandhi K; Vincent MS; King B
J Am Acad Dermatol; 2023 Feb; 88(2):395-403. PubMed ID: 36370907
[TBL] [Abstract][Full Text] [Related]
3. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
Guttman-Yassky E; Pavel AB; Diaz A; Zhang N; Del Duca E; Estrada Y; King B; Banerjee A; Banfield C; Cox LA; Dowty ME; Page K; Vincent MS; Zhang W; Zhu L; Peeva E
J Allergy Clin Immunol; 2022 Apr; 149(4):1318-1328. PubMed ID: 34863853
[TBL] [Abstract][Full Text] [Related]
4. Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open-Label, Phase 1 Study.
Martin DA; Telliez JB; Pleasic-Williams S; Zhang Y; Tierney B; Blatnik M; Gale JD; Banfield C; Zhou Y; Lejeune A; Zwillich SH; Stevens E; Tiwari N; Kieras E; Karanam A
J Clin Pharmacol; 2024 Jan; 64(1):67-79. PubMed ID: 37691236
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
King B; Zhang X; Harcha WG; Szepietowski JC; Shapiro J; Lynde C; Mesinkovska NA; Zwillich SH; Napatalung L; Wajsbrot D; Fayyad R; Freyman A; Mitra D; Purohit V; Sinclair R; Wolk R
Lancet; 2023 May; 401(10387):1518-1529. PubMed ID: 37062298
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
Hordinsky M; Hebert AA; Gooderham M; Kwon O; Murashkin N; Fang H; Harada K; Law E; Wajsbrot D; Takiya L; Zwillich SH; Wolk R; Tran H
Pediatr Dermatol; 2023; 40(6):1003-1009. PubMed ID: 37455588
[TBL] [Abstract][Full Text] [Related]
7. Expression of immune checkpoints in active nonsegmental vitiligo: a pilot study.
Awad SS; Touni AA; Gabril MY
Int J Dermatol; 2020 Aug; 59(8):982-988. PubMed ID: 32557594
[TBL] [Abstract][Full Text] [Related]
8. JAK inhibitors for the treatment of vitiligo.
Inoue S; Suzuki T; Sano S; Katayama I
J Dermatol Sci; 2024 Mar; 113(3):86-92. PubMed ID: 38326166
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Robinson MF; Damjanov N; Stamenkovic B; Radunovic G; Kivitz A; Cox L; Manukyan Z; Banfield C; Saunders M; Chandra D; Vincent MS; Mancuso J; Peeva E; Beebe JS
Arthritis Rheumatol; 2020 Oct; 72(10):1621-1631. PubMed ID: 32419304
[TBL] [Abstract][Full Text] [Related]
10. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
King B; Soung J; Tziotzios C; Rudnicka L; Joly P; Gooderham M; Sinclair R; Mesinkovska NA; Paul C; Gong Y; Anway SD; Tran H; Wolk R; Zwillich SH; Lejeune A
Am J Clin Dermatol; 2024 Mar; 25(2):299-314. PubMed ID: 38263353
[TBL] [Abstract][Full Text] [Related]
11. LITFULO
Gupta AK; Ravi SP; Vincent K; Abramovits W
Skinmed; 2023; 21(6):434-438. PubMed ID: 38051245
[TBL] [Abstract][Full Text] [Related]
12. Baseline serum and stool microbiome biomarkers predict clinical efficacy and tissue molecular response after ritlecitinib induction therapy in ulcerative colitis.
Hassan-Zahraee M; Ye Z; Xi L; Dushin E; Lee J; Romatowski J; Leszczyszyn J; Danese S; Sandborn WJ; Banfield C; Gale JD; Peeva E; Longman RS; Hyde CL; Hung KE
J Crohns Colitis; 2023 Dec; ():. PubMed ID: 38141256
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.
Ramírez-Marín HA; Tosti A
Drug Des Devel Ther; 2022; 16():363-374. PubMed ID: 35210753
[TBL] [Abstract][Full Text] [Related]
14. The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial.
Niezgoda A; Winnicki A; Kosmalski T; Kowaliszyn B; Krysiński J; Czajkowski R
Trials; 2019 Jan; 20(1):78. PubMed ID: 30683146
[TBL] [Abstract][Full Text] [Related]
15. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
Eisman S; Sinclair R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous JAK Expression in Vitiligo.
Abdel Motaleb AA; Tawfik YM; El-Mokhtar MA; Elkady S; El-Gazzar AF; ElSayed SK; Awad SM
J Cutan Med Surg; 2021; 25(2):157-162. PubMed ID: 33174479
[TBL] [Abstract][Full Text] [Related]
17. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
Sandborn WJ; Danese S; Leszczyszyn J; Romatowski J; Altintas E; Peeva E; Hassan-Zahraee M; Vincent MS; Reddy PS; Banfield C; Salganik M; Banerjee A; Gale JD; Hung KE
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2616-2628.e7. PubMed ID: 36623678
[TBL] [Abstract][Full Text] [Related]
18. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
[TBL] [Abstract][Full Text] [Related]
19. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.
Boukhedouni N; Martins C; Darrigade AS; Drullion C; Rambert J; Barrault C; Garnier J; Jacquemin C; Thiolat D; Lucchese F; Morel F; Ezzedine K; Taieb A; Bernard FX; Seneschal J; Boniface K
JCI Insight; 2020 Jun; 5(11):. PubMed ID: 32369451
[TBL] [Abstract][Full Text] [Related]
20. Senescence in the lesional fibroblasts of non-segmental vitiligo patients.
Rani S; Bhardwaj S; Srivastava N; Sharma VL; Parsad D; Kumar R
Arch Dermatol Res; 2017 Mar; 309(2):123-132. PubMed ID: 28078437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
